Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA.
Department of Psychology, Arizona State University, Tempe, AZ, USA.
Neuropharmacology. 2024 Jan 1;242:109773. doi: 10.1016/j.neuropharm.2023.109773. Epub 2023 Oct 21.
Individuals with opioid use disorder (OUD) frequently use other substances, including cocaine. Opioid withdrawal is associated with increased likelihood of cocaine use, which may represent an attempt to ameliorate opioid withdrawal effects. Clinically, 30% of co-using individuals take opioids and cocaine exclusively in a sequential manner. Preclinical studies evaluating mechanisms of drug use typically study drugs in isolation. However, polysubstance use is a highly prevalent clinical issue and thus, we established a novel preclinical model of sequential oxycodone and cocaine self-administration (SA) whereby rats acquired oxycodone and cocaine SA in an A-B-A-B design. Somatic signs of withdrawal were evaluated at 0, 22, and 24h following oxycodone SA, with the 24h timepoint representing somatic signs immediately following cocaine SA. Preclinically, aberrant glutamate signaling within the nucleus accumbens core (NAcore) occurs following use of cocaine or opioids, whereby medium spiny neurons (MSNs) rest in a potentiated or depotentiated state, respectively. Further, NAcore glial glutamate transport via GLT-1 is downregulated following SA of either drug alone. However, it is not clear if cocaine can exacerbate opioid-induced changes in glutamate signaling. In this study, NAcore GLT-1 protein and glutamate plasticity were measured (via AMPA/NMDA ratio) following SA. Rats acquired SA of both oxycodone and cocaine regardless of sex, and the acute oxycodone-induced increase in somatic signs at 22h was positively correlated with cocaine consumption during the cocaine testing phase. Cocaine use following oxycodone SA downregulated GLT-1 and reduced AMPA/NMDA ratios compared to cocaine use following food SA. Further, oxycodone SA alone was associated with reduced AMPA/NMDA ratio. Together, behavioral signs of oxycodone withdrawal may drive cocaine use and further dysregulate NAcore glutamate signaling.
患有阿片类药物使用障碍(OUD)的个体经常使用其他物质,包括可卡因。阿片类戒断与可卡因使用的可能性增加有关,这可能代表试图缓解阿片类戒断的影响。临床上,30%的共同使用者以顺序方式专门使用阿片类药物和可卡因。评估药物使用机制的临床前研究通常单独研究药物。然而,多药物使用是一个高度流行的临床问题,因此,我们建立了一个新的临床前模型,即顺序氧可酮和可卡因自我给药(SA),其中大鼠以 A-B-A-B 设计获得氧可酮和可卡因 SA。在氧可酮 SA 后 0、22 和 24 小时评估戒断躯体症状,24 小时时间点代表可卡因 SA 后立即出现的躯体症状。临床前研究表明,可卡因或阿片类药物使用后,伏隔核核心(NAcore)内的异常谷氨酸信号发生,其中中间神经元(MSNs)分别处于增强或去增强状态。此外,单独使用 SA 时,NAcore 胶质细胞谷氨酸转运通过 GLT-1 下调。然而,尚不清楚可卡因是否会加剧阿片类药物引起的谷氨酸信号变化。在这项研究中,测量了 SA 后 NAcore GLT-1 蛋白和谷氨酸可塑性(通过 AMPA/NMDA 比值)。大鼠无论性别如何都获得了氧可酮和可卡因的 SA,并且在 22 小时时急性氧可酮引起的躯体症状增加与可卡因测试阶段的可卡因消耗呈正相关。与食物 SA 相比,在氧可酮 SA 后使用可卡因会下调 GLT-1 并降低 AMPA/NMDA 比值。此外,单独使用氧可酮 SA 与降低 AMPA/NMDA 比值有关。总之,阿片类戒断的行为症状可能会促使可卡因使用,并进一步使 NAcore 谷氨酸信号失调。